Tag Archives: FRI

Drug delivery to the lungs of asthmatic patients using Dry Powder Inhalers: device and formulation matters!

This study will be presented at ERS 2019 at a thematic poster session on Tuesday October 1st between 12.50 pm and 2.40 pm. In a FRI deposition study,  the lung deposition patterns of extrafine ICS/LABA to non-extrafine ICS/LABA combination from two different DPIs in asthmatic patients were compared. Results showed that intrathoracic deposition with extrafine formulation… Continue Reading

Functional Respiratory Imaging (FRI) in combination with A.I. predicts early-life wildfire smoke exposure with accuracy and sensitivity in excess of 90%.

During the coming ERS conference ( Sept 29- Oct 2 in Madrid, Spain)  Fluidda will present the results of a study which investigated if FRI parameters can distinguish early-life wildfire smoke exposed animals from healthy controls. A cohort of 14  wildfire smoke exposed and 14 non-exposed, age and size matched adult female Rhesus monkeys was… Continue Reading

Differences found in lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using FRI.

This study will be presented at ERS 2019 at a thematic poster session on Monday September 30 between 12.50 pm and 2.40 pm. Functional Respiratory Imaging evaluated lung deposition patterns of extrafine ICS/LABA/LAMA with a pressurized metered dose inhaler (pMDI) and non-extrafine ICS/LABA/LAMA with a dry powder inhaler (DPI), in patients with stable COPD and… Continue Reading

Change in airway volume, measured with FRI, differentiates between stable and progressive IPF.

This study will be presented at ERS 2019 at a thematic poster session on Sunday September 29 between 12.50 pm and 2.40 pm. In a retrospective imaging analysis study, FRI ( Functional Respiratory Imaging )compared CT scans of IPF (Ideopathic Pulmonary Fibrosis) patients from two cohorts. 12 treatment-naïve IPF patients were sequentially identified at a… Continue Reading

Bronchial thermoplasty increases airway volume measured by Functional Respiratory Imaging (FRI)

In a  recently published study (click here for full article)10 patients with unstable, severe asthma were treated with bronchial thermoplasty of the left lung, while the right lung was used as an internal control. Changes in lung structure and function were assessed with Functional Respiratory Imaging (FRI). Significant differences between the treatment and control lungs were… Continue Reading

FLUIDDA attends the International Conference of Medical imaging with Deep Learning

During July 8-10 the International Conference of Medical imaging with Deep Learning takes place in London. The FLUIDDA team, specialised in using advanced A.I. algorithms to extract clinically relevant regional information from medial images, will be present to keep track on the latest developments in this exciting field of research. Continue Reading

FLUIDDA will be present at the Annual Drug Discovery & Development Symposium on Pulmonary Vascular Disease

This year’s symposium will take place in Paris on July 1-2. Each year the meeting brings leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial designs together with the pharmaceutical industry and regulatory authorities to help identify the most promising treatments for future development.  Fluidda is actively involved in clinical… Continue Reading

Jan de Backer, CEO and founder of Fluidda, speaks about the partnership with Materialise at the ATS conference.

De Backer states: “We are very excited and proud to enter into this new phase of partnership with Materialise. We share the vision that the medical field, and particularly respiratory healthcare imaging needs to evolve towards personalized, precision medicine through a value-based healthcare approach. We are confident that advanced imaging techniques, such as our Functional… Continue Reading

Friday June 7: Presentation FLUIDDA on CFD and lung deposition at the ECFS 2019 conference in Liverpool

At the yearly conference of the European Cystic Fibrosis Society which takes place from June 5-8 in liverpool (UK), the CEO and founder of Fluidda, Jan de Backer, will present new data obtained bij Functional Respiratory imaging ( FRI) on deposition patterns of CF-medication in the lung, and it’s clinical impact. The presentation will take… Continue Reading

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2019